HIV prevention drug hailed as breakthrough, but who gets access?
HEALTHBy Al Jazeera Africa — Al Jazeera Africa
The medical landscape in Zambia has received a significant boost with the regulatory approval and rollout of lenacapavir, a groundbreaking twice-yearly injectable pre-exposure prophylaxis (PrEP) designed to prevent HIV. Hailed globally as a monumental scientific leap, this long-acting formulation promises to alleviate the adherence hurdles associated with daily oral antiretroviral regimens, offering a discreet and highly effective shield against transmission. Yet, as the initial doses arrive in Lusaka and rural health centers alike, a pressing question looms over public health corridors: who will actually gain access to this lifesaving intervention? For Zambia, a nation that has made commendable strides in combating the HIV epidemic over the past two decades, the introduction of lenacapavir represents both an extraordinary opportunity and a logistical test. Ministry of Health officials, working alongside international partners and regulatory bodies like the Zambia Medicines Regulatory Authority (ZAMRA), have emphasized that initial distributions will strategically target high-risk groups, including young populations and vulnerable communities where infection rates remain disproportionately stubborn. By leveraging fast-track regulatory pathways, Zambia has positioned itself at the forefront of regional innovation in the global AIDS response. Despite the enthusiasm from policymakers, civil society organizations and healthcare workers have voiced pragmatic concerns regarding structural bottlenecks. The rollout of any advanced pharmaceutical intervention in resource-limited settings inevitably confronts hurdles such as cold-chain storage requirements, specialized healthcare training, supply chain reliability, and sustainable financing. Furthermore, historical disparities in healthcare access mean that urban centers often absorb new medical technologies much faster than remote, underserved provinces, risking a two-tiered system where innovation bypasses those who need